Sunday, September 28, 2014

Roche Breast Cancer Drug Appears to Greatly Extend Patients’ Lives

Perjeta, approved by the F.D.A. in 2012, prolonged median survival time about 16 months in a trial of 808 people with metastatic breast cancer.


via NYT > Business Day http://ift.tt/1rtmmr4








via WordPress http://ift.tt/1BqQPZm
Posted by at
Labels: , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)